

Special Issue

Therapeutic Studies from Pre-Clinical to Clinical (Phase I–IV) for Gastrointestinal Cancers

Message from the Guest Editor

Clinical trials remain the standard of care across the field of oncology to introduce novel treatment strategies and agents. These often evolve from promising preclinical data to drug development across Phase I–III trials, with varying levels of success. New treatments for all gastrointestinal malignancies are needed to prolong survival and maintain quality of life. In this Special Issue of *Current Oncology*, we invite authors to submit work focusing on therapeutic studies across the spectrum, from preclinical data to later-stage clinical trials, on gastrointestinal cancers. Original articles, as well as review articles detailing advances in novel therapeutics, are welcome. We look forward to receiving your contributions.

Guest Editor

Dr. Erica S. Tsang

Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada

Deadline for manuscript submissions

30 November 2025



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/219080

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)